wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q38779989-5D78E29E-335D-4F22-BB7E-048E0A0FBD82
Q38779989-5D78E29E-335D-4F22-BB7E-048E0A0FBD82
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38779989-5D78E29E-335D-4F22-BB7E-048E0A0FBD82
Drug Monographs: Olaratumab and Rucaparib.
P2860
Q38779989-5D78E29E-335D-4F22-BB7E-048E0A0FBD82
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38779989-5D78E29E-335D-4F22-BB7E-048E0A0FBD82
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
a501204dbb324f24344e1b4ce9a97f6a6f19cf2c
P2860
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation